Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026

Pulmonx (Nasdaq: LUNG) will report first quarter 2026 financial results after the close of trading on Wednesday, April 29, 2026.

Rhea-AI Summary

Pulmonx (Nasdaq: LUNG) will report first quarter 2026 financial results after the close of trading on Wednesday, April 29, 2026.

Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with a live and archived webcast available in the Investors section of the Pulmonx website.

Argus Apr 16 session

-2.67% close to close Open Argus

Details

News Market Reaction – LUNG

On Apr 16, the first trading day after this news, LUNG closed 2.67% below the previous close.

Data tracked by StockTitan Argus for the Apr 16 session.

Market Context

This announcement sets the timetable for Pulmonx’s first quarter 2026 results, with a release after ...

Analysis

This announcement sets the timetable for Pulmonx’s first quarter 2026 results, with a release after the close on April 29, 2026 and a conference call at 1:30 p.m. PT / 4:30 p.m. ET. It follows a prior earnings date notice that coincided with a 5.99% move. Investors may watch how upcoming results compare with recent guidance and consider the flexibility provided by the $200,000,000 shelf registration.

Key Figures

Earnings release date: April 29, 2026 Conference call time: 1:30 p.m. PT / 4:30 p.m. ET Shelf registration size: $200,000,000 +1 more

Earnings release date

April 29, 2026

First quarter 2026 financial results release after market close

Conference call time

1:30 p.m. PT / 4:30 p.m. ET

Management call to discuss Q1 2026 results

Shelf registration size

$200,000,000

Maximum aggregate offering under effective Form S-3/A

Current share price

$1.42

Price before Q1 2026 earnings date announcement

Previous Earnings date Reports

1 past event · Latest: Feb 20

Same Type 1 event

1. Feb 20

   Earnings date notice

   24h Move

   +6.0%

   Set Q4 and full-year 2025 report date with call and webcast details.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX^TM Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com. 

Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX^TM is a trademark of Pulmonx Corporation. 

Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Pulmonx (LUNG) release its Q1 2026 financial results?

Pulmonx will release Q1 2026 financial results after market close on April 29, 2026. According to the company, the release occurs after the close of trading with a follow-up conference call scheduled for that day.

What time is the Pulmonx (LUNG) earnings conference call on April 29, 2026?

The conference call begins at 1:30 p.m. PT / 4:30 p.m. ET on April 29, 2026. According to the company, management will discuss the quarter and host a live webcast for investors.

How can investors access the Pulmonx (LUNG) Q1 2026 webcast and archive?

Investors can access the live and archived webcast on Pulmonx's Investors website. According to the company, the webcast will be available in the Investors section at https://investors.pulmonx.com/.

Will Pulmonx (LUNG) discuss financial details during the April 29, 2026 call?

Yes. Management will discuss the company's financial results during the April 29, 2026 call. According to the company, the conference call is scheduled to review first quarter 2026 financial results after the market close.

Is the Pulmonx (LUNG) Q1 2026 event open to the public or just analysts?

The event is a public webcast accessible to investors and analysts. According to the company, the conference call will be webcast live and archived on the Pulmonx Investors website for public access.

Where is Pulmonx headquartered and which ticker trades its stock?

Pulmonx is headquartered in Redwood City, California, and trades on Nasdaq under the ticker LUNG. According to the company, the announcement was made from its Redwood City offices on April 15, 2026.